QIAGEN N.V. (QGEN)
Sector: Biological Products, (No Diagnostic Substances)
Industry: Medical - Diagnostics & Research
Qiagen N.V.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 6, 2026 | 50.42 | 50.50 | 50.26 | 50.33 | 3,394,158 |
| Nov 5, 2026 | 50.72 | 50.97 | 50.65 | 50.86 | 4,627,363 |
| Nov 4, 2026 | 50.76 | 50.88 | 50.65 | 50.83 | 3,228,032 |
| Nov 3, 2026 | 50.41 | 50.42 | 50.23 | 50.38 | 7,345,956 |
| Nov 2, 2026 | 50.50 | 50.50 | 50.30 | 50.35 | 3,572,386 |
| Oct 30, 2026 | 50.35 | 50.39 | 50.07 | 50.22 | 4,168,095 |
| Oct 29, 2026 | 50.18 | 50.41 | 50.10 | 50.34 | 3,549,441 |
| Oct 28, 2026 | 50.25 | 50.38 | 50.15 | 50.33 | 4,534,884 |
| Oct 27, 2026 | 50.32 | 50.39 | 50.17 | 50.17 | 4,256,934 |
| Oct 26, 2026 | 50.42 | 50.53 | 50.30 | 50.37 | 4,113,081 |
| Oct 23, 2026 | 50.38 | 50.45 | 50.33 | 50.39 | 7,144,401 |
| Oct 22, 2026 | 50.50 | 50.52 | 49.90 | 50.22 | 40,827,267 |
| Oct 21, 2026 | 48.12 | 50.25 | 46.89 | 50.00 | 12,529,750 |
| Oct 20, 2026 | 46.97 | 50.82 | 46.62 | 48.90 | 10,132,101 |
| Oct 19, 2026 | 46.18 | 46.91 | 45.84 | 46.55 | 2,159,801 |
| Oct 16, 2026 | 46.59 | 46.75 | 45.97 | 46.13 | 1,995,606 |
| Oct 15, 2026 | 45.96 | 46.48 | 45.59 | 46.17 | 1,312,644 |
| Oct 14, 2026 | 45.88 | 46.37 | 45.47 | 45.56 | 1,632,436 |
| Oct 13, 2026 | 45.77 | 45.79 | 44.97 | 45.44 | 1,437,226 |
| Oct 12, 2026 | 45.68 | 45.69 | 44.95 | 45.31 | 1,171,569 |
| Name | Shares | % | Source |
|---|---|---|---|
BlackRock, Inc. · also on 13F· may incl. warrants· filed Feb 2026 | 20.7M | 10.0% | 13G |
Massachusetts Financial Services Company · also on 13F· may incl. warrants· filed Jun 2026 | 12.4M | 6.0% | 13G |
WELLINGTON MANAGEMENT GROUP LLP | 12.4M | 6.0% | 13F |
PRICE T ROWE ASSOCIATES INC /MD/ | 11.4M | 5.5% | 13F |
PRINCIPAL FINANCIAL GROUP INC | 8.4M | 4.1% | 13F |
VANGUARD CAPITAL MANAGEMENT LLC | 6.2M | 3.0% | 13F |
BlackRock, Inc. | 5.9M | 2.9% | 13F |
MORGAN STANLEY | 5.0M | 2.4% | 13F |
Amundi | 4.6M | 2.2% | 13F |
EARNEST PARTNERS LLC | 4.6M | 2.2% | 13F |
Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide.
The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories.
It also provides Immune response consumables, such as interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; oncology and sexual and reproductive health consumables, inclsuing assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing.
The company offers research PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID/forensics assay consumables comprising short tandem repeat assays for human ID, and assays for food contamination; PCR instruments, including digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions.
It offers NGS gene panels, library prep kits and components, and whole genome amplification; DNA methylation analysis; QIAGEN consumables and instruments; bioinformatics solutions; and sequence-based assays forensic genetic genealog services. it provides software-as-a-service.
It serves molecular diagnostics and life sciences sectors.
The company was founded in 1984 and is headquartered in Venlo, the Netherlands.
based on 206.50M shares outstanding
NL30d Avg
6.16M
60d Avg
4.15M
90d Avg
3.71M